Phathom Pharmaceuticals (PHAT) announced that the U.S. Food and Drug Administration, FDA, has updated the Approved Drug Products with Therapeutic Equivalence Evaluations to accurately reflect the full 10-year period of non-patent New Chemical Entity, NCE, exclusivity for VOQUEZNA 10 mg and 20 mg tablets. The corrected Orange Book listing confirms that VOQUEZNA is entitled to NCE regulatory exclusivity through May 3, 2032, aligning with statutory requirements and reinforcing the long-term commercial runway for the first-in-class product.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Largest borrow rate increases among liquid names
- Phathom Pharmaceuticals Holds Annual Stockholders Meeting
- Phathom Pharmaceuticals price target raised to $17 from $12 at Craig-Hallum
- Phathom Pharmaceuticals Receives Buy Rating Amidst FDA Approval and Market Optimism for VOQUEZNA
- Phathom Pharmaceuticals Gains FDA Approval for VOQUEZNA® Exclusivity
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue